NDAINJECTIONINJECTABLE
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CARDIZEM (diltiazem hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology the therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for hypertension, chronic stable angina, angina due to coronary artery spasm. First approved in 1991.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM (diltiazem hydrochloride) is a non-dihydropyridine calcium channel blocker administered via injection that inhibits calcium ion influx into cardiac and vascular smooth muscle. It is indicated for hypertension, chronic stable angina, and angina due to coronary artery spasm, working by reducing peripheral vascular resistance and myocardial oxygen demand. The injectable formulation provides rapid hemodynamic effects in acute care settings.
$0.224MPart D
LOE ApproachingDeclining
Minimal commercial momentum with only 151 Part D claims annually; injectable formulation limits market reach as oral alternatives dominate, signaling small team focus on maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect…
Worked on CARDIZEM at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.